<DOC>
	<DOCNO>NCT01243892</DOCNO>
	<brief_summary>This Phase IV , open label , case-controlled , observational study evaluate age-adjusted cumulative height velocity pre-pubertal isolated growth hormone deficient ( IGHD ) idiopathic short stature ( ISS ) participant receive daily dos somatropin ( recombinant human growth hormone [ rhGH ] ; Nutropin ) use NuSpin device compare historical control national cooperative growth study ( NCGS ) .</brief_summary>
	<brief_title>A Study Evaluate Growth Participants Treated With Somatropin ( Nutropin ) Using NuSpin Device</brief_title>
	<detailed_description />
	<mesh_term>Dwarfism , Pituitary</mesh_term>
	<criteria>Bone age less equal ( &lt; /= ) 8 year ( female ) &lt; /= 10 year ( male ) determine xray left hand wrist obtain within six month enrollment Prepubertal male females physical exam Naive rhGH therapy Diagnosis IGHD ISS standard pharmacologic test discernable etiology short stature Height standard deviation score ( Ht SDS ) &lt; /= 1.5 ( &lt; /= 5th percentile ) IGHD participant ; Ht SDS &lt; /= 2.25 ( &lt; /= 1.2 percentile ) ISS participant Short stature etiologies IGHD ISS Participants receive chronic corticosteroid therapy ( great [ &gt; ] 3 month ) medical condition Participants active malignancy condition investigator believe would pose significant hazard participant rhGH initiate Females turner syndrome Any previous rhGH treatment Participation another simultaneous medical investigation trial Pediatric participant close epiphysis Participants prescribe rhGH dos outside variance NCGS control participant dose</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>14 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>